Holen Sie sich die Stockscreener-App
9.74
3.62%
0.34
Handel nachbörslich:
9.77
0.03
+0.31%
Zevra Therapeutics Inc Aktie (ZVRA) Neueste Nachrichten
Zevra Therapeutics (NASDAQ: ZVRA) posts $106.5M 2025 revenue; proxy items - Stock Titan
(ZVRA) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
JPMorgan Chase & Co. Has $4.18 Million Stock Holdings in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics Inc (1GDA.HM) Analyst insights, Price targets and Recommendations - Yahoo Finance Singapore
ZVRA Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Hennion & Walsh Asset Management Inc. Invests $1.25 Million in Zevra Therapeutics, Inc. $ZVRA - MarketBeat
Zevra Therapeutics Earnings Call Signals Profitable Turn - The Globe and Mail
ZVRA Stock Price, Quote & Chart | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - ChartMill
Zevra Therapeutics Inc (1GDA.HM) valuation measures and financial statistics - Yahoo Finance UK
Sentiment Recap: Will Zevra Therapeutics Inc benefit from geopolitical trendsTrade Entry Report & Community Supported Trade Ideas - baoquankhu1.vn
Nio, Zevra Therapeutics, Vertex Pharmaceuticals and other big stocks moving higher on Tuesday - MSN
Dividend Watch: Is Zevra Therapeutics Inc forming bullish engulfing patternsWeekly Risk Summary & Real-Time Buy Zone Alerts - baoquankhu1.vn
Zevra shares jump after selling SDX portfolio for $50M - MSN
Zevra Therapeutics Inc (1GDA.HM) stock historical prices and data - Yahoo Finance UK
Vanguard realignment: affiliates to report ZVRA holdings separately (ZVRA) - stocktitan.net
John B Bode At Zevra Therapeutics Executes Options Exercise, Realizing $326K - Benzinga
ZVRA Technical Analysis | Trend, Signals & Chart Patterns | ZEVRA THERAPEUTICS INC (NASDAQ:ZVRA) - chartmill.com
How (ZVRA) Movements Inform Risk Allocation Models - Stock Traders Daily
Is GeneDx (WGS) Using Sponsored NPC Testing to Quietly Strengthen Its Data Advantage? - Yahoo Finance
Hypersomnia Pipeline Advances with 3+ Companies Developing Innovative Therapies and Expanding Clinical Research | DelveInsight - Barchart
Citizens JMP Reiterates Buy Rating on Zevra Therapeutics (ZVRA), Keeps PT - MSN
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer under Nasdaq Listing Rule 5635(4) - MarketScreener
Zevra Ties NPC Testing Push To Valuation Gap And New CFO - Yahoo Finance
Zevra Therapeutics, Inc. (NASDAQ:ZVRA) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Published on: 2026-03-21 14:23:45 - baoquankhu1.vn
Assessing Zevra Therapeutics (ZVRA) Valuation After Recent Share Price Moves And Rare Disease Milestone - Sahm
Zevra Therapeutics Reports Inducement Grant to New Chief Financial Officer Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
GeneDx (WGS), Zevra Therapeutics (ZVRA) partner to launch sponsored genetic testing program for NPC - MSN
GeneDx (WGS), Zevra Therapeutics (ZVRA) Partner to Launch Sponsored Genetic Testing Program for NPC - Yahoo Finance
Zevra Therapeutics announced that, in accordance with Nasdaq Listing Rule 5635(C)(4), it has granted an inducement equity award to the company's new Chief Financial Officer. - Bitget
CFO at Zevra (NASDAQ: ZVRA) receives 300,000-share option grant - Stock Titan
Zevra Therapeutics (ZVRA) CFO Justin Renz files insider ownership report - Stock Titan
Zevra Therapeutics appoints Justin Renz as CFO - MSN
XOMA Royalty Reports 2025 Financial Results and Highlights Recent Business Achievements - GlobeNewswire Inc.
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook - Investing.com Nigeria
R. LaDuane Clifton (ZVRA) files Form 144 showing 11,000‑ and 3,000‑share sales - Stock Titan
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million and Settles Delaware Lawsuit 1 - Minichart
Zevra Therapeutics (NASDAQ:ZVRA) Shares Gap UpStill a Buy? - MarketBeat
Zevra Therapeutics Agrees to Sell SDX Portfolio to Commave Therapeutics for $50 Million - marketscreener.com
Zevra Shares Jump After Selling SDX Portfolio For $50M - Benzinga
Zevra Therapeutics, Inc.Common Stock (NQ: ZVRA - markets.chroniclejournal.com
BTIG initiates Zevra Therapeutics stock with buy on Miplyffa outlook By Investing.com - Investing.com Australia
Zevra Therapeutics (NASDAQ:ZVRA) Now Covered by BTIG Research - MarketBeat
Zevra Therapeutics (ZVRA) Sells Serdexmethylphenidate Portfolio to Commave for $50 Million - GuruFocus
Zevra Sells SDX Portfolio and Resolves Litigation - TipRanks
Zevra Therapeutics, Inc. $ZVRA Shares Bought by Kingdon Capital Management L.L.C. - MarketBeat
Zevra Therapeutics Sells SDX Portfolio to Commave Therapeutics for $50 Million - Quiver Quantitative
Zevra Therapeutics Sells Sdx Portfolio To Commave Therapeutics For $50 Million - tradingview.com
Zevra Sells SDX Portfolio to Commave for $50 Million, Ends Azstarys Pact and Repays Credit Facility - TradingView
ZVRA: BTIG Initiates Coverage with a "Buy" Rating and $23.00 PT - GuruFocus
Zevra (Nasdaq: ZVRA) sells SDX portfolio for $50M and repays $63M loan - Stock Titan
0.87%
0.11%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):